Songorine suppresses cell growth and metastasis in epithelial ovarian cancer via the Bcl ‑2/Bax and GSK3β/β‑catenin signaling pathways.

In conclusion, songorine exerted its anticancer effect through the GSK3β/β‑catenin and Bcl‑2/Bax signaling pathways. These results highlight the potential use of songorine as a novel therapeutic agent for EOC. PMID: 30896826 [PubMed - as supplied by publisher]
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research